On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 29 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 13, Issue 29, 17 July 2008
Rapid communications
Measles resurges in Italy: preliminary data from September 2007 to May 2008
  1. National Health Institute (Istituto Superiore di Sanità, ISS), Rome, Italy
  2. Postgraduate training program in Hygiene and Preventive Medicine, Tor Vergata University, Rome, Italy
  3. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  4. Bambino Gesù Children’s Hospital, Rome, Italy

Citation style for this article: Filia A, De Crescenzo M, Seyler T, Bella A, Ciofi Degli Atti ML, Nicoletti L, Magurano F, Salmaso S. Measles resurges in Italy: preliminary data from September 2007 to May 2008. Euro Surveill. 2008;13(29):pii=18928. Available online:
Date of submission: 11 July 2008

Following an incidence rate of 1/100,000 inhabitants in 2006 [1], Italy has been facing an upsurge of measles cases since September 2007, with outbreaks being reported in various regions. In Italy, measles vaccination is currently offered free of charge as combined measles-mumps-rubella (MMR) vaccine. The current national vaccination schedule recommends two doses of MMR vaccine, given respectively at 11-12 months and 5-6 years of age. Although childhood vaccination coverage has increased in recent years, reaching the national average of 88% in 2006 (source: Ministry of Health), with some regional variability (Figure 1), it is still below the target of 95% set by the National Measles Elimination Plan (MEP) launched in 2003 [2], and outbreaks continue to occur.

Figure 1. Vaccine coverage for the first MMR dose in children at 24 months of age, by region, Italy, 2006 (source: Ministry of Health)

Measles is a statutorily notifiable disease in Italy and in the last six-year period (2001-2006) an average of approximately 5,400 cases were reported annually, with a range from 215 cases (in 2005) to 18,020 cases (in 2002). According to the MEP, sensitivity, specificity, and timeliness of case reporting had to be improved and an enhanced surveillance system was therefore established in April 2007 [3]. According to the new system, physicians have to report suspected cases of measles within 12 hours and laboratory diagnostic testing (never requested previously) of blood, saliva and urine specimens is recommended for all sporadic cases. Outbreaks of suspected measles must be investigated with collection of specimens from at least 5-10 cases for confirmation and characterisation of the viral strain. Case report forms are collected centrally at the Ministry of Health and the National Health Institute (ISS). In order to support case ascertainment, a National Reference Laboratory was also established at the ISS.

This report is a preliminary description of the main epidemiological features of 2,079 cases reported to the enhanced measles surveillance system from September 2007 to May 2008. Cases with negative laboratory results have been excluded from the present analysis.

Place and time
Most reported cases occurred in the Piemonte region where a large outbreak began in September 2007, among a group of unvaccinated adolescents. [4].

The first case was a 17-year-old girl who developed symptoms two days after returning to Italy from the United Kingdom. In the following weeks and months the outbreak spread in Piemonte and increased measles activity was also reported in other regions. Since September, clusters of cases and larger outbreaks have been detected in 15 of the 21 Italian regions, with the monthly number of nationally reported cases reaching a peak of 434 cases in February 2008 (Figure 2).

Figure 2. Number of reported measles cases, by month, Italy, September 2007 - May 2008 (n=2079)

Over the nine-month period between 1 September 2007 and 30 May 2008, the estimated national cumulative incidence of measles was 3.4 cases per 100,000 inhabitants. Ninety-three percent of the cases were reported from six regions: Piemonte (966 cases – 47 % of the total), Lombardy (452 cases- 22%), Lazio (183 cases – 9% of total), Tuscany (128 cases – 6%), Emilia Romagna (113 cases – 5%) and Veneto (87 cases – 4%). The remaining cases were reported in Sardinia, P.A. Trento, Liguria, Valle D’Aosta, Marche, Abruzzo, Friuli-Venezia Giulia and Puglia [5].

Figure 3 shows the reported measles incidence per 100,000 inhabitants, by region, from September 2007 to May 2008. The highest incidence was reported from Piemonte followed by Lombardy, Tuscany and Lazio with 22.2, 4.7, 3.5 and 3.3 per 100,000 inhabitants respectively. 

Figure 3. Reported measles incidence per 100,000 inhabitants, by region, Italy, September 2007 - May 2008 (n=2079)

Transmission occurred in families, schools, hospitals, Roma/Sinti communities, and groups opposed to vaccination. In several regions cases also occurred among healthcare workers.

Age and vaccination status of cases
The age was reported for 2,008 cases (97%). The median age of cases was 17 years (range: 0-77 years). Almost 60% of cases (1,247) were aged 15-44 years (Figure 4). More specifically, 23% cases were aged 15-19 years, 15% were aged 20–24 years and 21% were aged 25-44 years.
Using national age-specific population figures as denominators, adolescents aged 15-19 years had the highest incidence rate, followed by infants (<1 year of age): 15.8/100,000 and 11.3/100,000 respectively.

Of the 1,932 cases for whom vaccination status was known, 1,772 (91.7%) were unvaccinated against measles at the time of infection, 130 (6.7%) had received only one dose of measles-containing vaccine (MCV), 12 (0.6%) had received two doses, while 18 (1%) were vaccinated but the number of doses was unknown (Figure 4).

Figure 4. Vaccination status of measles cases, by age-group, Italy, September 2007 - May 2008 (n=2079)

Microbiological investigation
Overall, 631 cases (30%) have been laboratory-confirmed. Preliminary molecular sequence analyses have identified genotype D4 in all positive samples tested up to early May 2008, with the exception of one sample from Emilia Romagna (genotype D8, 99% similar to viruses identified in 2007 in UK and in 2008 in Canada).

Hospitalisations and complications
Information on hospitalisations and complications was available for 1,227 cases. Of these, 371 (30%) were hospitalised. One case of encephalitis was reported as well as three cases of thrombocytopenia, 22 cases of pneumonia and 27 of otitis media.
One death due to measles pneumonia occurred in a laboratory-confirmed case in the Piemonte region, in an unvaccinated 10-year old child with a genetic immunodeficiency syndrome.

Public health measures
In each region, outbreak investigation and control measures were initiated by the local health authorities, according to the procedures indicated in the MEP and in the enhanced surveillance circular [2,3].  The type and extent of the public health response measures varied amongst local authorities but generally included basic epidemiologic investigation of suspected cases, identification and vaccination of susceptible contacts and laboratory confirmation of diagnosis. Primary care paediatricians and general practitioners were alerted for prompt reporting of measles cases and further investigation.

Although some progress has been made in Italy since the implementation of the MEP, as shown by the increase in routine immunisation coverage (from 84% in 2003 to 88% in 2006 in two-year old children, source: Ministry of Health) and the introduction of a routine second dose, the ongoing outbreaks indicate that much still needs to be done.
Molecular characterisation studies indicate that the first case reported in the Piemonte region was imported from the United Kingdom (genotype D4) [6] showing the importance of international efforts in controlling the current upsurge of the disease in Europe [7-9].
In Italy, adolescents and young adults have been particularly affected and most reported cases were unvaccinated or incompletely vaccinated. Nosocomial transmission occurred in several regions and cases were also reported among healthcare workers. As in 2006, cases have once again been reported among the Roma/Sinti population [10].
In conclusion, there is an urgent need to improve vaccination coverage with two doses of MMR in Italy, not only among children, but also among adolescents and young adults. More efforts should also be made to prevent measles transmission in healthcare settings by implementing effective infection control practices and ensuring that all healthcare workers are immune to measles, and to raise immunisation coverage in hard-to-reach populations. Surveillance and laboratory confirmation have improved but outbreak control should be further strengthened as viral transmission was not effectively interrupted. Finally, vaccination coverage in adolescents and young adults  and  second dose coverage in children should also be closely monitored. A national vaccination coverage survey is currently being conducted and will provide updated information on coverage in children and adolescents as well as on reasons for non-vaccination.

The authors gratefully acknowledge the support of the Italian Ministry of Health (Ufficio V). We also thank the local and regional health authorities for providing data, Antonella Marchi, Eleonora Benedetti, Paola Bucci and Claudia Fortuna (ISS) for laboratory surveillance, Grazia Caleo and Gloria Nacca (ISS) for help with data entry, and Mark Muscat (EUVAC.NET) for his helpful comments on the manuscript.

1. EUVAC.NET. Measles surveillance annual report 2006. Available from:
2. Presidenza del Consiglio dei Ministri. Repertorio Atti n. 1857 del 13 novembre 2003. Piano Nazionale per l’ Eliminazione del Morbillo e della Rosolia Congenita (in Italian) Available from:
3. Italian Ministry of Health. Circular no.DGPREV.V/10606/P/I.4.c.a.9. of 20 April 2007. Piano Nazionale per l’Eliminazione del Morbillo e della Rosolia Congenita: Istituzione di un Sistema di Sorveglianza Speciale per Morbillo (in Italian). Available from:
4. Filia A, Barale A, Malaspina S, Montu D, Zito S, Muscat M, Ciofi Degli Atti ML. A cluster of measles cases in Northern Italy: a preliminary report. Eurosurveillance 2007; 12 (48):pii=3318. Available from:
5. Caputi G, Tafuri S, Chironna M, Martinelli D, Sallustio A, Falco A, et al. An outbreak of measles including nosocomial transmission in Apulia, south-east Italy, January-March 2008 - a preliminary report. Euro Surveill. 2008;13(16):pii=18839. Available from:
6. Editorial team. Measles once again endemic in the United Kingdom. Euro Surveill. 2008;13(27):pii=18919. Available from:
7. Health Protection Agency. Confirmed cases of measles in England and Wales – an update to end-May 2008. Health Protection Report (HPR) June 2008;2(25). Available from:
8. Richard JL, Masserey-Spicher V, Santibanez S, Mankertz A. Measles outbreak in Switzerland - an update relevant for the European football championship (EURO 2008). Euro Surveill. 2008;13(8):pii=8043. Available from:
9. Schmid D, Holzmann H, Abele S, Kasper S, König S, Meusburger S, et al. An ongoing multi-stes linked to non-immune anthroposophic communities in Austria, GermanApril 2008. Euro Surveill.2008;13(16):pii=18838. Available from:    
10. Filia A, Curtale F, Kreidl P, Morosetti G, Nicoletti L, Perrelli F, et al. Cluster of measles cases in the Roma/Sinti population, Italy, June-September 2006. Euro Surveill. 2006;11(41):pii=3062. Available for:

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.